ACADIA PHARMACEUTICALS INC. Debt Securities, Available-for-sale, Realized Loss
ACADIA PHARMACEUTICALS INC. (ACAD) reported Debt Securities, Available-for-sale, Realized Loss of $500.00 thousand for the 3-month period ending 2023-03-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss · last filed 2025-02-27
- ACADIA PHARMACEUTICALS INC. debt securities, available-for-sale, realized loss for the quarter ending 2023-03-31 was $500.00K.
| Period end | Debt Securities, Available-for-sale, Realized Loss 3 month |
|---|---|
| 2023-03-31 | $500.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |